GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK on Wednesday lifted its full-year forecast, boosted by reinvigorated demand for its blockbuster Shingrix vaccine, days after overhauling the business with the spinoff of its consumer health unit.

GSK lifts full-year forecast, days after consumer health spinoff

Alkermes

Biogen

Bristol-Myers

Teva Pharmaceutical

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

GSK PLC (LSE:GSK, NYSE:GSK)'s second-quarter figures will provide the first clues as to whether the business will flourish or founder following the £30bn demerger of its consumer business, Haleon. Remember, chief executive Dame Emma Walmsley and her finance team have re-set guidance - and it suggested the drugs giant will positively flourish as an independent entity.

GSK: Investors will be looking for early signs that drugs giant will hit newly issued sales and earnings targets

Investors may be warming to the company's spin-off of its consumer healthcare division.

Why GlaxoSmithKline Stock Jumped 25% on Thursday

Schrodinger 

Biotech stocks have rebounded lately and are poised to keep surging, so it's a good time to buy biotech stocks on the dip. The post 3 Biotech Stocks to Buy on the Dip appeared first on InvestorPlace.

3 Biotech Stocks to Buy on the Dip

Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.

GSK Completes Demerger of Consumer Healthcare Business

Maker of Sensodyne, Advil, and TUMS becomes one of the world's leading independent consumer health companies Demerger from GSK plc (GSK) now complete WARREN, N.J. , July 18, 2022 /PRNewswire/ -- Today, Haleon (LSE/NYSE: HLN) launches as an independent company 100% focused on consumer health, completing its demerger from GSK.

Haleon launches with purpose to deliver better everyday health with humanity

Monday, July 18, is set up to be a big day for GlaxoSmithKline (NYSE: GSK) and the London Stock Exchange.

GSK spinoff starts trading at LSE – what you need to know

Europe's biggest listing in a decade, Haleon, started trading on the London Stock Exchange on Monday. Haleon in the consumer-health business spinoff of GSK GSK, -19.57%.

GSK spinoff Haleon starts trading in largest European listing in a decade

Pfizer

Consumer health group Haleon PLC (LSE:HLN, NYSE:HLN) has become the largest company to list in London for over a decade after formally completing its spin-out from GSK PLC (LSE:GSK, NYSE:GSK). It will not be issuing new shares as part of its flotation.

Haleon makes market debut as GSK and Pfizer in complete consumer health spin-off

Things are looking up for GSK and its chief Emma Walmsley as the British drugs giant prepares to spin off its consumer health business on Monday in London's biggest listing in a decade and the company's most radical shake-up in 20 years.

After bruising year, GSK approaches consumer split in better health

Following the spin-off of its consumer healthcare partnership, GSK PLC (LSE:GSK, NYSE:GSK) will be the pure-play drug company many investors — including some pushy activist funds — have been pushing for years. With the demerger and a solid performance in recent quarters, chief executive Emma Walmsley seems to have silenced most of her critics.

What 'New GSK' will look like after the Haleon spin-off

GSK PLC (LSE:GSK, NYSE:GSK) begins the first part of the process to spin off Haleon PLC (LSE:HLN, NYSE:HLN), its consumer healthcare joint venture with Pfizer Inc (NYSE:PFE), on Friday, July 15. After investors recently approved the demerger, the spin-off process is being done via a scrip dividend, where investors in GSK will get a share in Haleon for each one they own as of the close on Friday.

GSK begins Haleon spin-off process ahead of Monday's listing

PHILADELPHIA--(BUSINESS WIRE)-- #Flu--GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses

GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses

GSK leads the race to deliver a vaccine for an untreated infectious disease.

How Its New Vaccine Could Propel GSK's Growth

AbbVie

Gilead Sciences

You'll either need a decent chunk of change or some patience.

How to Earn $10,000 a Year in Passive Retirement Income

Caterpillar

Enbridge

Johnson & Johnson

Oracle

Constellation Brands

State Street

Planning for retirement can feel overwhelming in bear markets, but these seven retirement stocks can provide a boost to savings. Caterpillar (CAT): The heavy equipment manufacturer is enjoying strong demand for products.

7 Retirement Stocks to Buy in July

PHILADELPHIA--(BUSINESS WIRE)-- #Diversity--GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community

GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community

GSK PLC (LSE:GSK, NYSE:GSK) is chasing a label extension for its shingles vaccine in Japan. It wants doctors to be able to prescribe Shingrix to at-risk groups over the age of 18, including those with compromised immune systems.

GSK applies for shingles drug label expansion in Japan

Sanofi

Sanofi and GSK's joint Covid-19 vaccine has finally produced data that could challenge the dominance of the Pfizer and Moderna vaccines.

GSK and Sanofi's Covid-19 Vaccine Could Pose a Challenge to Pfizer and Moderna

Sanofi SNY, +0.38% SAN, +3.70% and GlaxoSmithKline GSK, +1.86% said Friday that their experimental bivalent COVID-19 booster had a 72% efficacy rate against omicron, and they now plan to submit the data to regulators. The recombinant protein booster protects against the original strain of the virus as well as the beta variant, a strain of the virus that is no longer in circulation but that shares mutations with omicron that allow both variants to "escape" antibodies.

Sanofi, GSK say their next-generation COVID-19 booster has 72% efficacy against omicron

Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate.  "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-.

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Hedge funds are increasingly attracted to 'New GSK' as it spins-off its Consumer Healthcare business into Haleon PLC. This and the "markedly improved" sentiment towards the FTSE 100 group, were some of the main takeaways for the pharmaceutical team at Jefferies in discussions with its institutional clients following its recent note outlining why the shares offer "compelling value" ahead of the 18 July spin-off.

Investor views on GSK 'significantly swing towards positive' ahead of Haleon spin-off

GlaxoSmithKline PLC kept an 'equal weight' stance with Barclays ahead of the demerger of Haleon, its consumer health business, in July. Analysts at the bank “harmonised” GSK Consumer Health forecasts ahead of Haleon's launch, with projected sales of £10.7bn, underlying earnings (EBITDA) of £2.6bn and net income of £1.5bn.

GlaxoSmithKline needs to be better in pharrma arena, suggests Barclays

When Haleon PLC is spun off from GSK PLC (LSE:GSK, NYSE:GSK) next month it is expected to be the biggest stock market listing of the past decade. The indicative valuation is £42bn, which begs the question why did the UK drugs giant and its partner Pfizer turn down a £50bn offer from Unilever?

News for GlaxoSmithKline Stock (GSK)